Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
---|---|
Information provided by: | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
ClinicalTrials.gov Identifier: | NCT00147446 |
There is a growing body of literature showing that stressful life events can increase the risk of developing exacerbations and new brain lesions among people with multiple sclerosis. The purpose of this study is to examine the hypothesis that stress management programs can reduce the occurrence of new brain lesions and exacerbations. We will also examine potential immune and neuroendocrine pathways.
Condition | Intervention | Phase |
---|---|---|
Multiple Sclerosis |
Behavioral: Cognitive Behavioral Stress Management for MS Behavioral: Wait List Control |
Phase II |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Single Blind (Outcomes Assessor), Dose Comparison, Parallel Assignment, Efficacy Study |
Official Title: | Phase II Study of the Effects of Stress Management on Neuroimaging, Clinical, Immune and Psychosocial Outcomes |
Estimated Enrollment: | 120 |
Study Start Date: | May 2005 |
Study Completion Date: | January 2009 |
Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Individual Cognitive Behavioral Stress Management
|
Behavioral: Cognitive Behavioral Stress Management for MS
16 weekly meetings with a health psychologist
|
2: No Intervention
Wait List Control
|
Behavioral: Wait List Control
1-Day workshop that occurs at the end of the trial containing all intervention information
|
MS is a frequently disabling autoimmune disease affecting approximately 350,000 people in the United States. More than two decades of research has consistently shown a relationship between stressful life events (SLEs), in particular non-traumatic family and work stressors, and subsequent clinical exacerbation. Furthermore, we have shown that non-traumatic SLEs increase the risk of the subsequent appearance of new gadolinium enhancing (Gd+) magnetic resonance imaging (MRI) brain lesions, an early marker of MS inflammation and blood-brain barrier (BBB) breakdown. The purpose of this study is to determine the efficacy of cognitive behavioral stress management for MS (CBSM-MS) in reducing the occurrence of new brain lesions in people with relapsing forms of MS. Patients must have a documented new Gd+ MRI brain lesion or clinical exacerbation within the previous 12 months to be enrolled.
One hundred and twelve patients will be enrolled for 12 months. Patients will be randomly assigned to either an intensive CBSM-MS program, consisting of 16 individual meetings with a behavioral medicine specialist, or a condensed CBSM-MS program, consisting of a one-day workshop offered after the 10th month of participation.
Outcomes include MRI, clinical neurological end-points, and psychosocial functioning. We will also enhance our understanding of mechanisms by examining potential psychosocial, immune, and endocrine mediators of the relationship between SLEs and clinical and neuroimaging markers of MS inflammation.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
UCSF Behavioral Medicine Research Center | |
San Francisco, California, United States, 94121 | |
United States, Illinois | |
Northwestern University, Department of Preventive Medicine | |
Chicago, Illinois, United States, 60611 | |
United States, Washington | |
MS Center at Evergreen Medical Center | |
Kirkland, Washington, United States, 98034 |
Principal Investigator: | David C. Mohr, Ph.D. | Northwestern University |
Study Director: | Emily Gagen | Northwestern University |
Principal Investigator: | David Daikh, MD | University of California, San Francisco |
Responsible Party: | Northwestern University ( David C. Mohr, Ph.D./Professor ) |
Study ID Numbers: | SIMS, R01 HD043323 |
Study First Received: | September 2, 2005 |
Last Updated: | May 19, 2009 |
ClinicalTrials.gov Identifier: | NCT00147446 History of Changes |
Health Authority: | United States: Federal Government; United States: Institutional Review Board |
Stress Stress Management Behavioral Medicine Multiple Sclerosis Psychoneuroimmunology |
Autoimmune Diseases Multiple Sclerosis Demyelinating Diseases Demyelinating Autoimmune Diseases, CNS |
Stress Sclerosis Autoimmune Diseases of the Nervous System |
Pathologic Processes Autoimmune Diseases Multiple Sclerosis Immune System Diseases Demyelinating Diseases |
Nervous System Diseases Demyelinating Autoimmune Diseases, CNS Sclerosis Autoimmune Diseases of the Nervous System |